Coherus Oncology, Inc. (NASDAQ:CHRS) Holdings Raised by Cwm LLC

Cwm LLC increased its position in shares of Coherus Oncology, Inc. (NASDAQ:CHRS) by 96.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 49,793 shares of the biotechnology company’s stock after acquiring an additional 24,468 shares during the period. Cwm LLC’s holdings in Coherus Oncology were worth $40,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of CHRS. Point72 Asset Management L.P. acquired a new position in Coherus Oncology during the fourth quarter worth about $7,291,000. Tang Capital Management LLC grew its holdings in Coherus Oncology by 55.3% during the fourth quarter. Tang Capital Management LLC now owns 3,650,000 shares of the biotechnology company’s stock worth $5,037,000 after acquiring an additional 1,300,000 shares during the period. Millennium Management LLC grew its holdings in Coherus Oncology by 31.6% during the fourth quarter. Millennium Management LLC now owns 1,049,603 shares of the biotechnology company’s stock worth $1,448,000 after acquiring an additional 252,092 shares during the period. Stonepine Capital Management LLC acquired a new position in Coherus Oncology during the fourth quarter worth about $345,000. Finally, Northern Trust Corp increased its stake in Coherus Oncology by 12.2% in the 4th quarter. Northern Trust Corp now owns 1,006,505 shares of the biotechnology company’s stock worth $1,389,000 after purchasing an additional 109,770 shares in the last quarter. 72.82% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Coherus Oncology news, Director Mats Wahlstrom sold 99,988 shares of the firm’s stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $0.74, for a total transaction of $73,991.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 8.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Coherus Oncology in a research note on Tuesday, April 29th. UBS Group reissued a “neutral” rating and issued a $1.05 price target (down previously from $1.50) on shares of Coherus Oncology in a research note on Thursday, April 24th. Finally, Wall Street Zen cut Coherus Oncology from a “hold” rating to a “sell” rating in a research note on Tuesday, May 20th.

Coherus Oncology Trading Down 6.6%

Shares of CHRS opened at $0.88 on Monday. The business’s 50-day moving average price is $0.83 and its 200 day moving average price is $0.95. The stock has a market capitalization of $101.76 million, a P/E ratio of -0.78 and a beta of 0.89. Coherus Oncology, Inc. has a 1-year low of $0.66 and a 1-year high of $2.43.

Coherus Oncology (NASDAQ:CHRS) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04). The business had revenue of $7.60 million during the quarter, compared to analysts’ expectations of $59.79 million. During the same period in the previous year, the firm earned ($0.32) EPS. On average, research analysts predict that Coherus Oncology, Inc. will post -1.05 earnings per share for the current year.

Coherus Oncology Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.